philipn / Dipyridamole for COVID-19 b744bfe1c427b723a5216d343e5383bd9807ecdc

Create Draft
Some more details, references
Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this

Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic.

Mechanism of potential benefit

See the research overview by Yogendra Kanthi, Jason S. Knight, et. al: "New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm"

Clinical trials

A list of clinical trials of dipyridamole for COVID-19:

See also

Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic.

Mechanism of potential benefit

Dipyridamole is said to "[have the] potential to inhibit multiple processes that have been recently linked to COVID-19 severity," such as purinergic signaling (related to inflammation and thrombosis), and may help induction of type 1 IFNs.

Dipyridamole has also been shown to have direct anti-viral effects against SARS-CoV-2, showing anti-SARS-CoV-2 activity in vitro in Vero cells. Dipyriadmole's anti-SARS-CoV-2 activity may occur via binding to the SARS-CoV-2 protease Mpro (see Fig. 1B).

Research overviews:

Clinical trials

A list of clinical trials of dipyridamole for COVID-19:

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.